Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma

ConclusionsVolumetric imaging at 3 months can serve as an early biomarker to predict long-term sensitivity to everolimus treatment. Everolimus may represent a safe treatment option to decrease the growth of NF2-related VS in patients who have stable hearing and neurological condition. TRN: NCT01345136 (April 29, 2011).

http://link.springer.com/10.1007/s11060-024-04596-4

Source: Journal of Neuro-Oncology - February 19, 2024 Category: Cancer & Oncology Source Type: research